Oxford Biomedica clinches second gene therapy deal – The Times
The TimesOxford Biomedica clinches second gene therapy dealThe TimesAn Oxford University spin-off that specialises in gene therapy applications has won a $100 million contract from Bioverativ, an American company specialising in treatments for haemophi… Continue reading
